À¯¹æ¾Ï ȯÀÚ¿¡¼ Á¾¾ç Ç¥ÁöÀڷμ Ç÷¾× ³» TGF-¥â1ÀÇ ºÐÆ÷¿¡ °üÇÑ ¿¬±¸
Plasma TGF-¥â1 as a Tumor Marker in Breast Cancer Patients
¼Ò¼Ó »ó¼¼Á¤º¸
ÀÌÈ¿µ
¶ó¼±¿µ/°ø¼öÁ¤/¾ÈÁß¹è/½É±¤¿ë/¹ÚÁØ¿À/±ÇÇöÀÚ/À¯³»Ãá/Á¤¼÷Á¤
KMID : 0360319980300050935
Abstract
¼·Ð
¾ÏÀÇ ¹ß»ý°ú ¼ºÀå °úÁ¤¿¡¼ ¾Ï¼¼Æ÷°¡ Á¤»óÀûÀÎ ¼ºÀå Á¶Àý °úÁ¤À» ¹þ¾î³ª Áö¼ÓÀûÀ¸·Î ¼ºÀå
ÇÏ´Â ±âÀüÀ¸·Î´Â Á¾¾ç À¯ÀüÀÚ ¹× Á¾¾ç ¾ïÁ¦ À¯ÀüÀÚ¿Í ÀÇ °ü·Ã¼º ¿Ü¿¡ ¼¼Æ÷ ¼ºÀå ÀÎÀÚÀÇ °ü
·Ã¼º¿¡ ´ëÇÑ ¿¬±¸°¡ º¸°íµÇ¾ú´Ù. ¼¼Æ÷ ¼ºÀå ÀÎÀÚ´Â Ç÷¾× ³» Á¸ÀçÇÏ´Â polypeptide, Á¶Á÷ ¾×,
¼¼Æ÷ ÃßÃâ¹° µîÀ¸·ÎºÎÅÍ ºÐ¸®ÇÒ ¼ö ÀÖÀ¸¸ç ÁÖµÈ ÀÛ¿ëÀº DNAÇÕ¼º °úÁ¤¿¡¼ ¼¼Æ÷ ºÐ¿À» Á¶
ÀýÇϸç ÀϺδ Á¤»ó¼¼Æ÷°¡ ¾Ï¼¼Æ÷·Î ÇüÁú ÀüȯµÇ´Âµ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÑ´Ù. ¾Ï¼¼Æ÷´Â ¹è¾ç
½Ã¿¡ Á¤»ó ¼¼Æ÷¿¡ ºñÇØ ¿ÜºÎÀû ¼ºÀå ÀÎÀÚÀÇ °ø±ÞÀ» ´ú ÇÊ¿ä·Î Çϸç ÀÌ´Â ¾Ï¼¼Æ÷°¡ ½º½º·Î
¼ºÀå ÀÎÀÚ¸¦ »ý¼ºÇÏ°í ÀÖÀ½À» ½Ã»çÇÏ°í ÀÌ ¼ºÀå ÀÎÀÚµé Áß Æ¯È÷ ÇüÁú Àüȯ ¼ºÀå ÀÎÀÚ
(transforming growth factor-¥â : TGF-¥â) °¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÑ´Ù. TGF-¥â´Â ¸Å¿ì ´Ù¾ç
ÇÑ ±â´ÉÀ» °¡Áø 25kDÀÇ homodimeric peptide·Î¼ ¼¼Æ÷ÀÇ ºÐÈ, ¼ºÀåÀ» Á¶ÀýÇÒ »Ó ¾Æ´Ï¶ó
´ëºÎºÐÀÇ »óÇÇ ¼¼Æ÷¿Í ÀÓÆÄ°è ¼¼Æ÷ÀÇ ¼ºÀåÀ» ¾ïÁ¦ÇÏ´Â °·ÂÇÑ ¼ºÀå ¾ïÁ¦ ÀÎÀÚ·Î ¾Ë·ÁÁ® ÀÖ
´Ù. ±×·¯³ª TGF-¥âÀÇ °¡Àå ÁÖµÈ ÀÛ¿ëÀÌ »óÇÇ ¼¼Æ÷ Áõ½ÄÀ» ¾ïÁ¦ÇÏ´Â ÀÛ¿ëÀÌÁö¸¸ »óÇÇ ¼¼Æ÷
¿¡¼ À¯·¡ÇÑ ¾Ï ¼¼Æ÷´Â TGF-¥âÀÇ ¼ºÀå ¾ïÁ¦ ÀÛ¿ë¿¡ ÀúÇ×¼ºÀ» º¸ÀÌ´Â ¹Ù, ÀÌ·¯ÇÑ TGF-¥â
ÀÇ ÀúÇ×¼º ȹµæÀº ¾ÏÈ °úÁ¤¿¡¼ Áß¿äÇÑ ´Ü°è·Î Àνĵǰí ÀÖ´Ù. Áï ¾Ç¼º Á¾¾çÀÌ Áõ½ÄÇϱâ
À§Çؼ´Â ¾Ï ¼¼Æ÷¿Í ÁÖÀ§ Á¤»ó Á¶Á÷ »çÀÌ¿¡ ¸Å¿ì º¹ÀâÇÏ°í Á¤±³ÇÑ Àü´Þ ü°è°¡ ¼º¸³µÇ¾î¾ß
Çϴµ¥ ÀÌ °úÁ¤¿¡¼ TGF-¥â´Â ¿©·¯ ¼¼Æ÷ÀÇ ¼ºÀåÀ» ¾ïÁ¦ÇÏ´Â ±â´ÉÀ» º¸ÀδÙ(autocrine
pathway). ±×·¯³ª ÀÏ´Ü¾Ï ¼¼Æ÷°¡ TGF-¥âÀÇ ¼ºÀå ¾ïÁ¦ ÀÛ¿ë¿¡ ÀúÇ×¼ºÀ» ³ªÅ¸³»´Â °æ¿ì,
TGF-¥â¸¦ °ú´Ù ¹ßÇöÇÏ°Ô µÈ´Ù. TGF-¥âÀÇ ¼ºÀå ¾ïÁ¦ ÀÛ¿ë¿¡ ÀúÇ×¼ºÀ» ȹµæÇÑ ¾Ï¼¼Æ÷¿¡¼
ºÐºñµÇ´Â TGF-¥â´Â ¼¼Æ÷ÀÇ ¼ºÀåÀ» ¾ïÁ¦Çϱ⺸´Ù´Â ¿ÀÈ÷·Á ÁÖÀ§ Ç÷°ü »ý¼ºÀ» ÃËÁøÇÏ°í ¸é
¿ª °¨Áö ±â´ÉÀ» ¾ïÁ¦ÇÏ¿© Á¾¾ç Áõ½ÄÀ» ÃËÁøÇÏ°Ô µÈ´Ù(paracrine pathway). ¾Ï ¹ß»ý °úÁ¤¿¡
¼ TGF-¥âÀÇ ´Ù¾çÇÑ ÀÛ¿ë°ú ÇÔ²² ¹è¾çµÈ ¾Ï¼¼Æ÷¿¡¼ TGF-¥â1 geneÀÇ
mRNA°ú ¹ßÇö TGF-¥â1ÀÇ ºÐºñ Áõ°¡°¡ º¸°íµÇ¾ú´Ù. ¾Æ¿ï·¯ TGF-¥â
1 mRNAÀÇ °ú¹ßÇöÀÌ human renal cancer, breast cancer, scirrhous gastric
cancer µî¿¡¼ º¸°íµÇ¾úÀ¸³ª ¾ÆÁ÷±îÁö ¾Ï ȯÀÚ Ç÷¾×¿¡¼ TGF-¥â1 °ú´Ù ¹ßÇö
ÀÇ ÀÓ»óÀû Àǹ̷μ ¶Ç´Â Ä¡·á ¸ñÇ¥(target)·Î¼ÀÇ ¿¬±¸´Â °ÅÀÇ ½ÃÇàµÇÁö ¾Ê¾Ò´Ù. µû¶ó¼ º»
¿¬±¸¿¡¼´Â À¯¹æ¾Ï ȯÀÚÀÇ Ç÷¾×¿¡¼ ¾ïÁ¦¼º Á¾¾ç ¼ºÀå ÀÎÀÚÀÎ TGF-¥â1ÀÇ ¹ß
Çöµµ¿Í ±× Áø´ÜÀû, Ä¡·áÀû ¸ñÇ¥·Î¼ÀÇ Àǹ̸¦ Á¶»çÇÏ¿´´Ù.
Purpose : Transforming Growth Factor-¥â1(TGF-¥â1) is the
most potent inhibitor of the progression of normal mammary epithelial cells through the
cell cycle. However, advanced breast cancers are mostly refractory to TGF-¥â mediated
growth inhibition and produce large amounts of TGF-¥â, which may enhance tumor cell
invasion and metastasis by its effects on extracellular matrix. Yet, little is known about
the association of TGF-¥â1 with progression of malignant disease in vivo.
In this study, we evaluated the preoperative and postoperative plama level of
TGF-1 in breast cancer and analyzed the utility of plasma TGF-¥â
1 as possible tumor marker.
Materials and Methods : ELISA(enzyme-linked immunosorbent assay) was used to
measure plasma TGF-¥â1 level in 45 newly diagnosed breast cancer
patients and in 15 normal healthy people, and the results were compared with
clinicopathologic characteristics.
Results : The mean plasma TGF-¥â1 levels were 1.73¡¾0.47 ng/ml in
normal people and 5.05¡¾1.41 ng/ml in breast cancer patients. In 37 operated patients,
the preoperative plasma TGF-¥â1 level was 6.34¡¾1.34 ng/ml and
decreased to 4.48¡¾1.07 ng/ml in patients with follow-up after surgery and 4.74¡¾0.79
ng/ml in patients with chemotherapy. However, there was no significant correlation
between plasma TGF-¥â1 level and known prognostic factors including
tumor size, LN involvement, tumor grade, hormone receptor status, and pathology.
Conclusion : These findings suggest that the plasma TGF-¥â1 level can
be a tumor marker in breast cancer patients and the association with progression of
breast cancer will be explored in future studies.
Å°¿öµå
TGF-¥â; Breast cancer; Carcinogenesis; Tumor marker; Prognostic factor;
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸